Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) is a clinical research site located in Boston, Massachusetts, United States 02215.
Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) has participated in 1 clinical trials.
Therapeutic areas: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia.
Sponsors: Regeneron Pharmaceuticals.
Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) has 1 clinical trials on record. Their work covers Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia.
Dana Farber Cancer Institute (Massachusetts General Hospital and Beth Israel) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.